Skip Navigation


Annals of Oncology Advance Access originally published online on October 31, 2007
Annals of Oncology 2007 18(12):2041; doi:10.1093/annonc/mdm499
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/2041    most recent
mdm499v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horacek, J. M.
Right arrow Articles by Pudil, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horacek, J. M.
Right arrow Articles by Pudil, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation

The first 10% of the full text of this article appears below.

Cardiotoxicity is a potentially serious complication of oncology treatment. Myeloablative preparative regimen (PR) followed by hematopoietic cell transplantation (HCT) represents high risk for the development of cardiotoxicity [1]. Various methods have been recommended for monitoring cardiotoxicity in oncology. Recently, the applicability of cardiac troponins (cTnT, cTnI) has been investigated in this . . . [Full Text of this Article]

funding

J. M. Horacek1,4,*, M. Tichy2,4, L. Jebavy1,4, M. Ulrychova2 and R. Pudil3

1 2nd Department of Medicine–Clinical Hematology
2 Institute of Clinical Biochemistry and Diagnostics
3 1st Department of Medicine, Faculty of Medicine and University Hospital, Sokolska 581, 50005 Hradec Kralove
4 Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 50001 Hradec Kralove, Czech Republic

* (E-mail: jan.hor@post.cz)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. M. Horacek, M. Tichy, R. Pudil, and L. Jebavy
Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity
Ann. Onc., September 1, 2008; 19(9): 1656 - 1657.
[Full Text] [PDF]